Status: Recruiting
PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)
The Phase II clinical trial of the oral hexavalent reassortant rotavirus attenuated live vaccine (Vero Cells) will be conducted in infants aged 6 to 12 weeks. This study will evaluate the immunogenicity and safety of the investigational vaccine in healthy infants through a randomized, double-blind, active-controlled trial.
Participants needed: 400
Trial details
Phase: Phase 2Age: 6-12Biological sex: AllType: InterventionalSponsor: Sinovac Life Sciences Co., Ltd.Updated: Aug 22, 2025Locations: 1
Eligibility criteria
Healthy infants aged 6 to 12 weeks. [+3]
Previous vaccination with any rotavirus vaccine. [+19]